Glucose, cholesterol and blood pressure in type II diabetes : a longitudinal observational study comparing patients with and without severe mental illness by Smith, Robert et al.
This is a repository copy of Glucose, cholesterol and blood pressure in type II diabetes : a 
longitudinal observational study comparing patients with and without severe mental illness.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/148729/
Version: Accepted Version
Article:
Smith, Robert, Han, Lu orcid.org/0000-0001-7198-3380, Ali, Shehzad 
orcid.org/0000-0002-8042-3630 et al. (6 more authors) (2019) Glucose, cholesterol and 
blood pressure in type II diabetes : a longitudinal observational study comparing patients 
with and without severe mental illness. Journal of psychiatric and mental health nursing. 
ISSN 1351-0126 
https://doi.org/10.1111/jpm.12546
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
For Peer Review
Glucose, cholesterol and blood pressure in type II diabetes: 
a longitudinal observational study comparing patients with 
and without severe mental illness 
Journal: Journal of Psychiatric and Mental Health Nursing
Manuscript ID JPM-18-0398.R2
Manuscript Type: Original Article
Keywords: Epidemiology, Physical Health, Primary Care
 
Journal of Psychiatric and Mental Health Nursing
Journal of Psychiatric and Mental Health Nursing
For Peer Review
1
1 Title
2 Glucose, cholesterol and blood pressure in type II diabetes: a longitudinal observational study 
3 comparing patients with and without severe mental illness 
4 Accessible Summary
5 What is known on the subject? 
6  People with severe mental illness (SMI) have a life expectancy 15-20 years less than the 
7 general population, partly due to increased risk of physical disease, including type II diabetes 
8 (T2DM) and cardiovascular disease.
9  Little is known about changes in cardiovascular risk factors over time in people with both 
10 T2DM and SMI compared to those with T2DM and no SMI.
11 What this paper adds to existing knowledge?
12  We investigated whether levels of cardiovascular risk factors, cholesterol, HbA1c, systolic and 
13 diastolic blood pressure associated with adverse clinical outcomes are different in T2DM 
14 patients with and without SMI. We found significant differences in systolic blood pressure 
15 and HbA1c between the two groups.
16  55% and 29% of T2DM patients with comorbid SMI are at increased risk of adverse clinical 
17 outcomes due to sub-optimal HbA1c and systolic blood pressure levels respectively.
18 What are the implications for practice?  
19  Many patients with T2DM and SMI have higher levels of cardiovascular risk compared to 
20 patients with T2DM only, and good management of risk factors is therefore particularly 
21 important in patients with both conditions.
22  Achieving better control of HbA1c levels is likely to be central to addressing inequalities in 
23 outcomes for patients with both SMI and T2DM.
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24 Abstract
25 Introduction: Patients with both severe mental illness (SMI) and type II diabetes (T2DM) have lower 
26 life expectancy than patients with T2DM alone, partly due to poor control of cardiovascular risk 
27 factors in comorbid patients.
28 Aim: To compare levels of cholesterol, HbA1c and blood pressure in T2DM patients with and without 
29 SMI.
30 Method: We analysed longitudinal clinical records of 30,353 people with T2DM (657 with SMI;29,696 
31 controls without SMI) between 2001 and 2013 using the Clinical Practice Research Datalink (CPRD). 
32 We used mixed effects regression models to compare cardiovascular risk factors between SMI and 
33 controls. 
34 Results: Patients with SMI had lower mean systolic blood pressure (SBP) ": -2.49; SE=0.45 P=<0.01) 
35 and were more likely to have extreme (high and low) values of HbA1c and SBP (OR 1.38, 95%CI: 
36 1.16,1.64 and 1.76:1.40,2.21 respectively).
37 Discussion: People with T2DM and SMI have similar average values of cardiovascular risk factors to 
38 people with T2DM alone but are more likely to have values of HbA1c and SBP indicating increased risk 
39 of adverse clinical outcomes. 
40 Implications for Practice:  Improved management of cardiovascular risk factors in general, glycaemic 
41 control in particular, is central to addressing the increased risk of adverse outcomes in people with 
42 both SMI and T2DM.
43 Keywords: Epidemiology, Physical Health, Primary Care
44
45
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46 Relevance statement 
47 People with comorbid T2DM and SMI are more likely to have extreme values of HbA1c and systolic 
48 blood pressure that are associated with adverse clinical outcomes. Better management of these risk 
49 factors should be ensured to address inequalities in physical health outcomes in patients with SMI 
50 and T2DM. 
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52 Introduction
53 People with severe mental illness (SMI) including schizophrenia, bipolar disorder and other forms of 
54 psychosis have a life expectancy 15-20 years less than the general population (Brown et al., 2010). 
55 Reduction of excess mortality in those with mental disorders has been identified as an important 
56 global health issue, identifying risk factors for earlier mortality can lead to development of effective 
57 interventions to address physical health inequality among those with mental disorder (Liu et al., 
58 2017). Most of the premature deaths are caused by complications of physical health conditions 
59 (Reilly et al., 2015, De Hert et al., 2009). These include insulin resistance and relative insulin 
60 deficiency forms of diabetes mellitus, type II diabetes mellitus (T2DM), the prevalence of which is 
61 twice as great in those with SMI than in the general population (Reilly et al., 2015). This increased 
62 prevalence of T2DM is attributed due to a variety of factors including genetic predisposition (De Hert 
63 et al., 2009), the metabolic effects of atypical antipsychotics (Smith et al., 2008), higher levels of 
64 obesity and poor diet (Osborn et al., 2007), lower levels of physical activity (Daumit et al., 2005) and 
65 the greater barriers that disadvantaged or marginalised groups face in navigating the healthcare 
66 system (Dixon-Woods et al., 2006). People with the co-occurrence of T2DM and SMI (comorbid 
67 T2DM and SMI) have around a 50% increased risk of mortality compared with people with T2DM 
68 alone (Kontopantelis et al., 2015, Wu et al., 2015, Vinogradova et al., 2010), but the underlying 
69 mechanism for this difference is not well understood. Candidate causes include higher levels of 
70 smoking (McDonald, 2000), poor management of cardiovascular risk factors (including glycaemia, 
71 cholesterol and blood pressure), and higher prevalence of other comorbid conditions (Vinogradova 
72 et al., 2010). Patients with comorbid SMI and T2DM are less likely to receive standard levels of 
73 diabetes care, with 45% not receiving any diabetes care and the least chance of receiving specialised 
74 interventions for cardiovascular treatments (De Hert et al., 2011). Controlling HbA1c and optimising 
75 lipid and blood pressure management reduces the risks of microvascular and macrovascular 
76 complications, which remain the main cause of morbidity and mortality in patients with T2DM (Ray 
77 et al., 2009, Khaw et al., 2001, Collaborators, 2008, Group, 1998). However, the evidence for 
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78 appropriate management of cardiovascular risk factors in patients with diabetes and SMI is 
79 inconclusive, particularly in the UK (Dixon et al., 2004, Wake et al., 2016). A small study in the United 
80 States showed that patients with SMI had lower levels of HbA1c compared to patients without SMI 
81 (Dixon et al., 2004), and a recent larger study suggested that people with T2DM taking antipsychotic 
82 medication have lower cholesterol, HbA1c and blood pressure levels compared to matched controls 
83 not taking antipsychotic medication (Wake et al., 2016). There is, however, little evidence at a 
84 population level on the changes in cardiovascular risk factors over time in those with SMI that 
85 develop T2DM compared to those with T2DM and no SMI. Using population level data of clinical 
86 records from primary care, we can assess variation in cardiovascular risk factors that may be a 
87 contributing factor to the excess mortality for people with SMI and T2DM at a population level.  
88 Identification of the candidate causes of the mortality gap can then be targeted through evidence-
89 based interventions (Lawrence and Kisely, 2010).      
90 The aim of this study was to investigate whether there is a difference in cardiovascular risk factors in 
91 adults with diabetes and SMI compared with adults with diabetes without SMI, and whether these 
92 risk factors change over time. 
93
94 Materials and Methods
95 Data Source 
96 We used data from Clinical Practice Research Datalink (CPRD) which contains primary care records 
97 for around 6.9% of the UKs patients (Herrett et al., 2015). Clinical care processes, diagnoses, 
98 measurements and test results are recorded using a hierarchical set of clinical codes (Read codes). 
99 Prescriptions for medicine are recorded using British National Formulary (BNF) codes. The sample 
100 used in this study was taken from 125 out of 674 practices in CPRD (19%), all practice included in the 
101 sample were based in England. Practices were selected to be proportionally representative of the 
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102 proportional distribution of all the 674 practices in CPRD in terms of level of socioeconomic 
103 deprivation (using practice postcode linked to Index of Multiple Deprivation) and practice size in 
104 terms of number of registered patients. All patients records at participating practices were added to 
105 the CPRD database, the criteria for inclusion in our sample were patients with at least one of the 
106 following long-term conditions documented using Read codes in their primary care record: asthma, 
107 atrial fibrillation, coronary heart disease (CHD), chronic kidney disease (CKD), chronic obstructive 
108 pulmonary disease (COPD), diabetes, epilepsy, heart failure, hypertension, hyperthyroidism, learning 
109 disability, osteoporosis, SMI or stroke. For the purpose of this study, we selected all patients in the 
110 sample who had diabetes, with or without other long-term conditions.
111 Cohort
112 Patient records were included in the study if they had a Read code indicating a diagnosis of T2DM. 
113 Patients with diabetes diagnosis Read codes that did not distinguish diabetes type were excluded. 
114 Patients with SMI were identified using Read codes indicating a diagnosis of SMI (schizophrenia, 
115 bipolar disorder or other forms of psychoses). Patients with T2DM but without SMI were classified as 
116 controls. Patients with diagnosis dates for either condition that matched their date of entry into a 
117 CPRD practice (1% of all patients) were excluded from the analysis as their diagnosis date was not 
118 deemed reliable, as this suggests the diagnosis was made prior to the patient joining the study 
119 practice.
120 Data were extracted for 1st April 2001 to 31st March 2013. Not all participants entered the study in 
121 2001; for patients with both SMI and type II diabetes (T2DM), patients entered the study on the year 
122 of their diagnosis of the second condition, either SMI or T2DM, depending on the order in which the 
123 patient was diagnosed. The year of diagnosis of T2DM was the baseline year in patients without SMI. 
124 All eligible patients (18+ years) upon entering the database were followed up until the end of the 
125 study (2013), unless they died or moved to a non-study practice. 
126
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127 Outcomes
128 Diabetes-related measurements included serum cholesterol levels, HbA1c levels, and systolic and 
129 diastolic blood pressure (SBP and DBP respectively), which are predictive of future complications (Ray 
130 et al., 2009, Khaw et al., 2001, Collaborators, 2008, Group, 1998). National guidelines generally aim 
131 to control these parameters below recommended thresholds, but previous studies have suggested 
132 that very low levels of these parameters are not always associated with optimal outcomes. We 
133 therefore examined both mean levels of these parameters and values identified in previous studies 
134 as being associated with increased risk of mortality in patients with diabetes: HbA1c <6.25% or 
135 >7.75% (<45 or >61mmol/mol), serum cholesterol <2.5mmol/l or >6.5mmol/l , SBP <115mmHg and 
136 DBP <72.5mmHg or >92.5mmHg (Lipska et al., 2013, Kontopantelis et al., 2015). Repeated measures 
137 were used for each year for each patient during the study period. When multiple values were 
138 available in the same year for the same patient, the mean of the patients values were used. 
139 Covariates
140 Data were extracted from patients records for the following covariates: gender, age, body mass 
141 index (BMI) (Bhaskaran et al., 2013), smoking behaviour, comorbid long-term illnesses, prescription 
142 of diabetes medication, antipsychotic medication, antidepressant medication and cardiovascular 
143 medication were recorded if a prescription code was reported at any time within a given year. Area 
144 deprivation for patient postcode was measured in quintiles using Index of Multiple Deprivation (IMD) 
145 as a measurement of patients socioeconomic status  (Noble et al., 2006). Ethnic group was identified 
146 using Read codes in patients records but because ethnicity is typically poorly reported in primary 
147 care, for those with missing data in CPRD, we acquired the information using Hospital Episodes 
148 Statistics (HES) using a standardised approach (Mathur et al., 2014). Smoking status was taken from 
149 the patients clinical record. If smoking status was missing in the corresponding year, the last 
150 recorded smoking status was used from the patients historical record.
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151 Several comorbid conditions were used to control for differences in underlying risk factors between 
152 those with and without SMI. The comorbid conditions included asthma, coronary heart disease 
153 (CHD), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), epilepsy, heart 
154 failure, hypertension, hyperthyroidism, osteoarthritis (OA), osteoporosis, or stroke.  Read codes to 
155 identify all diagnoses of health conditions were taken from previously validated lists (Reilly et al., 
156 2015). All Read code lists used in this study are available to download from www.clinicalcodes.org. 
157 Statistical analysis
158 We calculated proportions or means and standard deviations (SD) for each outcome. Median and 
159 interquartile ranges (IQR) are reported for skewed data. Characteristics of adults with SMI and 
160 controls are presented as measured at baseline year. Between-group differences were assessed over 
161 the whole study period using 2 test for proportions. Students paired t-test was used to compare 
162 mean values and Wilcoxon rank sum test was used for skewed data. Differences in prevalence of 
163 comorbidities were compared using a logistic regression whilst adjusting for age and gender. 
164 We used a two-level linear mixed model for each continuous variable (cholesterol, HbA1c, SBP or 
165 DBP), reporting beta ":% and its standard error (SE), and to examine high risk values we used two-
166 level logistic mixed effects models for each outcome, reporting odds ratios (OR) and 95% confidence 
167 intervals (95% CI). Results of the regression models are reported over the whole study of all patients. 
168 We also describe changes over time in both groups over the course of each year of follow up. The 
169 linear and logistic mixed effects models were specified to the following nested structure: nested 
170 within different general practices (level 1) and individuals over time (level 2); hence, individual-level 
171 and practice level random intercepts and individual random slopes were specified in the model. We 
172 fitted increasingly complex models: 1) bivariate model; 2) multivariate model which also adjusted for 
173 mean age (in years), gender, ethnicity, socioeconomic status (the most affluent quintile as the 
174 reference group), mean BMI, presence or absence of comorbidities, and smoking status as 
175 covariates; 3) as model 2 plus number of years of diabetes diagnosis and presence or absence of 
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176 cardiovascular medication that interacts with cholesterol (statins and other lipid lowering agents) 
177 and blood pressure (ACE inhibitors, K blockers, : blockers, calcium channel blocker, thiazide diuretic, 
178 loop diuretics, other lipid lowering and statins). We did not explore the confounding effect of SMI 
179 patients taking antipsychotic medication or mood-stabilisers on outcomes because only a very small 
180 proportion of our control group had been prescribed antipsychotics or mood-stabilisers, compared to 
181 nearly half of those in the SMI group leading to co-linearity between antipsychotic medication or 
182 mood-stabilisers and diagnosis of SMI in our cohort.
183 Due to the nature of the CPRD data and the statistical models used, data were not considered 
184 missing for medication and comorbidities, as the absence of a Read code may identify the patients as 
185 not having a diagnosis of a condition or prescription of medication in the given year and could not be 
186 used to distinguished missing data. Missing data were only considered where records were missing 
187 for BMI, smoking, ethnicity, cholesterol, HbA1c, SBP or DBP. There was no difference in the 
188 proportion of patients in each group with missing data (supplement 1). To account for missing data, 
189 we used multiple imputations using a chained command (MICE) and presented the imputed results 
190 as the main analysis (White et al., 2011). The MICE repeatedly sampled from the distribution of the 
191 four outcome variables: cholesterol, HbA1c, SBP and DBP and all other covariates included in model 3 
192 were entered to the imputation model. Sensitivity analysis was conducted for complete data in all 
193 analyses, the statistical significance of analyses was the same in both complete data and imputed 
194 data. All analyses were conducted using STATA v14.1. An K level of 5% was used.
195
196 Results
197 Missing data
198 There was no difference in the proportion of patients in each group with missing measurements of 
199 cholesterol (df=1, N=3353, X2=1.0, P=0.3), HbA1c (df=1, N=3353, X
2=0.6, P=0.4), SBP (df=1, N=3353, 
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200 X2=0.6, P=0.4) or DBP (df=1, N=3353, (X2=1.7, P=0.2) for the study period (supplement 1). Data for 
201 ethnicity was missing for 16% of patients with SMI and 17% of controls (df=1, N=3353, X2=0.3, P=0.6). 
202 For BMI and smoking status; 22% of SMI patients and 24% of controls had at least one missing value 
203 in any one year, again this was not different between groups (df=1, N=3353, X2=0.6, P=0.4). 
204 ***Insert table 1***
205
206 Patient characteristics at baseline year
207 There were 30,353 T2DM patients identified within the dataset, with 657 (2%) having a diagnosis of 
208 SMI. For patients with both conditions, most (73%) were diagnosed with SMI first. The characteristics 
209 of the cohort are displayed in table 1. Compared to controls, people with SMI and T2DM were on 
210 average younger, more likely to be female, to live in an area of high deprivation and to smoke, and 
211 less likely to be of white British ethnicity. Mean BMI was higher in people with SMI. Those with SMI 
212 were diagnosed with diabetes at a younger age (mean 54.7 years compared to 59.6 years for 
213 controls) but the number of years since diagnosis with diabetes was not significantly different.  
214 Compared to controls, a higher proportion of people in the SMI group had prescriptions for diabetic 
215 medication and antidepressants, but a lower proportion had prescriptions for cardiovascular 
216 medication. There was no significant difference in the number of additional comorbidities between 
217 groups, but people with SMI and T2DM were more likely to have CKD, dementia, depression, 
218 epilepsy, hypothyroidism or stroke and less likely to have CHD, hypertension or osteoarthritis. There 
219 were no significant differences between groups in the prevalence of asthma, cancer, COPD, heart 
220 failure, or osteoporosis.   
221 ***Insert table 2***
222 ***Insert table 3***
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223
224 Differences in cardiovascular risk factors 
225 Over the whole follow-up period there were no significant differences between people with SMI and 
226 controls in mean level of cholesterol ":<()/)6 SE=0.05, P=0.19), HbA1c (-0.08; 0.05, P=0.09) or DBP (-
227 0.30; 0.25, P=0.21), but mean SBP was significantly lower in people with SMI  (-2.50, 0.44  '0.001) 
228 (table 2). Over the whole study period and controlling for all covariates, people with SMI and T2DM 
229 were more likely to have higher risk for high or low HbA1c (OR 1.38; 95% CI=1.18, 1.64) (table 2), a 
230 difference between groups observed in low and high HbA1c values with 55% of people with SMI at 
231 risk (table 3). There were similar findings for SBP, with difference between groups observed in low 
232 SBP values (1.76; 1.40, 2.21), with 29% of people with SMI at risk (table 3). There was no statistically 
233 significant difference between group in cholesterol or DBP in specifications 1, 2 or 3 of the multilevel 
234 mixed effect binary logistic regression model. Full results of all three models including covariates are 
235 available in the appendix (supplement 2).
236 ***Insert figure 1***
237 ***Insert figure 2***
238 Changes over time in groups
239 Differences for some outcomes, however, changed over time. For cholesterol, mean levels fell in 
240 both groups over study period (figure 1a). For HBA1c, mean levels in both groups increased over time 
241 from similar baselines, but levels in the control group increased at a faster rate; after 12 years mean 
242 levels were higher for controls compared to SMI patients, but this difference failed to reach statistical 
243 significance (figure 1b). For SBP, mean levels changed over time in both groups, but levels were 
244 similar in both groups after 12 years (figure 1c). For DBP, mean levels decreased over time in both 
245 groups, and were not significantly different at any time (figure 1d).  The proportion of all patients in 
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246 both groups with levels of outcomes associated with a higher risk of adverse events decreased over 
247 time of follow-up for cholesterol and HbA1c and increased for SBP and DBP (figure 2).  
248
249 Discussion
250 Main findings
251 When examining differences between groups in the values of cardiovascular risk factors, we found 
252 that people with SMI had similar mean values of blood cholesterol, HbA1c and DBP. After controlling 
253 for the confounding effect of difference in patient characteristics, socioeconomic level, medication 
254 and comorbidities, people with SMI had significantly lower values of SDP compared to controls. In 
255 relation to values of cardiovascular risk factors associated with increased risk of diabetes 
256 complications or mortality, people with SMI appear to be more likely to have at-risk values of HbA1c 
257 due to high and low levels, and SBP due to low levels compared to controls. This suggests that, 
258 despite similar values in mean scores, a higher proportion of those with low values of cardiovascular 
259 risk factors in HbA1c and SBP may contribute to the health inequalities in physical health outcomes 
260 observed for people with SMI and T2DM. 
261 Study Strengths and limitations 
262 We analysed a longitudinal dataset containing rich information on individual patients and their 
263 management within primary care, adjusting for important comorbidities and differences in 
264 characteristics of the groups of interest. In addition to exploring differences in mean values of 
265 cardiovascular risk factors, we also examined differences in proportions of patients with risk factor 
266 levels associated with increased risk of complications and mortality (Kontopantelis et al., 2015). 
267 Lower values below thresholds of cardiovascular risk factors appear to indicate similar risks for 
268 microvascular and macrovascular complications in T2DM patients as has been shown in 
269 cardiovascular factors used for this study, we selected thresholds that represented a significant 
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270 increased risk of earlier mortality compared to a reference value in a study of 246,544 T2DM patients 
271 (Kontopantelis et al., 2015). While we considered values of cardiovascular risk factors, it is possible 
272 that cardiovascular risk factor variability differs between our study groups, glycaemic variability, 
273 which has been associated with adverse outcome (Cardoso et al., 2018) possibly contributes to 
274 health inequality in people with SMI and T2DM could be an area of future research.  This study is the 
275 first to explore if those with SMI and T2DM are at increased risk to adverse clinical outcomes due to a 
276 combination of low or high levels of HBA1c and SBP, compared to only higher as previously reported.      
277 The study has several limitations. First, the number of adults with comorbid SMI and diabetes was 
278 relatively small and fell during follow-up. Only 5.0% of the SMI cohort remained at 12 years of follow-
279 up, compared to 8.9% in the cont ol group. Attrition in this study is primarily due to patients entering 
280 into the study after 2001, leading to fewer follow up years in these patients. For example, a patient 
281 with a T2DM diagnosis in 2010 only had a maximum follow-up of 3 years to 2013 (i.e. the date of 
282 data cut). Other contributions to attrition were patients dropping out from the practice, due to 
283 mortality or leaving the practice. In addition, two practices included in our sample did not have data 
284 uploaded to CPRD for the final year of follow up. With a larger sample, we may have been able to 
285 identify statistically significant differences in markers of cardiovascular risk between the two groups, 
286 although we would have to consider whether any such differences were clinically meaningful. 
287 Similarly, our results with respect to the increased risk of extreme values of risk factors in patients 
288 with SMI may be affected by the relatively small sample. Second, our dataset depends on accurate 
289 and complete recording by primary care practices and missing data is a particular issue for some 
290 important covariates, for example ethnicity (Mathur et al., 2014), smoking behaviour, and body mass 
291 index (Bhaskaran et al., 2013). The proportion of missing data was not found to be different between 
292 groups. We used multiple imputation to infer robust variances and no differences were detected 
293 comparing findings drawn from imputed and non-imputed results. Third, although the sampled 
294 practices were nationally representative in terms of patient demographics, they might not be 
295 nationally representative in terms of the quality of management of patients with T2DM and/or SMI, 
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296 although we have no reason to believe that they were not. Fourth, we do not know whether the data 
297 we analysed were differentially recorded between our study groups, and it is possible that 
298 adjustment for differences in patient characteristics resulted in residual confounding. Fifth, we could 
299 only adjust for area-level deprivation which will not have accounted for individual differences in 
300 socio-economic status. Finally, in our main analysis, duration of follow-up for patients without SMI 
301 began at the time of diagnosis with diabetes, whereas a quarter of patients with SMI had pre-existing 
302 diabetes. However, we retained comorbid SMI patients who developed diabetes first to analyse all 
303 patients with both diagnoses and controlled for duration of illness in our regression models. Despite 
304 limitations relating to attrition and sample size of comorbid SMI patients in the study, the results of 
305 differences between groups appears to be robust; where there were no statistical differences 
306 between groups in the regression models, mean beta and OR suggest no differences of clinical 
307 importance.    
308
309 What the study adds to the existing evidence
310 We estimate that approximately 55% of T2DM patients with comorbid SMI are at increased risk of 
311 microvascular and macrovascular complications due to high or low HbA1c levels. This represents a 
312 higher risk compared to T2DM patients with no SMI. Our analysis of longitudinal data suggests this 
313 risk remains stable for SMI patients from onset of diagnosis. Approximately 29% of T2DM patients 
314 with comorbid SMI are also at increased risk due to levels of SBP associated with adverse outcomes, 
315 again a higher proportion of those at risk compared to T2DM patients with no SMI. To our 
316 knowledge, this is the first study to explore extreme (high and low) values related to cardiovascular 
317 risk, the presence of which may be obscured when mean values are examined.     
318     
319 Implications
320 Our study is the first to comparatively evaluate markers of cardiovascular risk factors in people with 
321 SMI using longitudinal data. Two previous studies, one a case-control study (matching patients with 
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322 schizophrenia with controls on factors including BMI) and one a cross-sectional study, observed 
323 significantly lower HbA1c levels in SMI groups compared to non SMI groups (Dixon et al., 2004, Wake 
324 et al., 2016). We observed no significant initial difference in mean HbA1c between groups, but we 
325 included patients without schizophrenia and did not follow the same matching approach. We also 
326 found that over time, HbA1c levels in patients with SMI increased at a slower rate than for patients 
327 without. The case-control study also compared serum cholesterol levels and blood pressure in 
328 patients with schizophrenia to controls. The findings were similar to our study; compared with 
329 controls, average blood pressure was lower in patients with schizophrenia but there were no 
330 differences for serum cholesterol.  
331 People with SMI face a greater risk of developing several chronic physical diseases, including 
332 diabetes, and tend to have poorer outcomes for those conditions compared to the general 
333 population. Both SMI and diabetes are mainly managed in the community setting in the England, and 
334 primary care has a central role in coordination and continuity of care for patients with multiple 
335 conditions (Ricci-Cabello et al., 2015). It is therefore crucial that mental health nurses are aware that 
336 a higher proportion of their patients with T2DM and SMI are at risk of adverse outcomes due to their 
337 cardiovascular risk factors. Better management of all cardiovascular risk factors should be ensured, 
338 particularly controlling of extreme (high and low) values of HbA1c, to address inequalities in physical 
339 health outcomes in patients with SMI and T2DM. We found that overall the management of 
340 cardiovascular risk factors was similar in diabetes patients with and without SMI, although those with 
341 SMI appear to be at increased risk of HbA1c and SBP values associated with increased risk of adverse 
342 clinical outcomes. However, further investigation of the contributors to the physical health gap in 
343 patients with SMI and diabetes is needed.   
344 Conclusions 
345 Overall, our findings suggest that people with SMI are more likely to have HbA1c and SBP values 
346 associated with poor cardiovascular outcomes in the context of diabetes. They are also more likely to 
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347 live in deprived areas, to smoke, and to be obese. Conversely, they are less likely to have 
348 hypertension or coronary heart disease. After controlling for such risk factors, patients with SMI have 
349 similar average levels of cholesterol, HbA1c and DBP but lower SBP. This suggests that patients with 
350 SMI and diabetes are managed to a similar standard to other patients with diabetes, and that other 
351 factors are maybe responsible for the gross inequalities in physical health outcomes observed for 
352 people with SMI.  However, both HbA1c and SBP in patients with SMI may be over-treated, which may 
353 increase the risk of adverse clinical outcomes. This warrants further investigation, including the 
354 contributing factors that increase risk of mortality, microvascular events, macrovascular events and 
355 diabetes-related hospital admissions in patients with comorbid SMI.    
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Table 1 Characteristics of cohort at baseline year
Characteristics SMI (n=657) Control (n=29 696) P value
Age years, mean (SD) 59.1 (14.1) 63.6 (13.4) <0.001*
Females, n (%) 356 (54) 13267 (45) <0.001**
Ethnicity, n (%)
White
Mixed
South Asian
Black
Chinese/other
unknown
448 (68)
6 (1)
45 (7)
42 (6)
12 (2)
104 (16)
21299 (72)
147 (1)
1846 (6)
1028 (4)
451 (2)
4925 (17)
<0.001**
IMD quintile, n (%)
1 (most affluent)
2
3
4
5 (most deprived)
Missing
88 (13)
97 (15) 
113 (17)
154 (23)
195 (30)
10 (2)
5647 (19)
6151 (21)
5732 (19)
6062 (20)
5930 (20)
274 (1)
<0.001**
Mean BMI (kg.m2), mean (SD)
Missing n (%)
31.6 (6.8)
10 (1.5)
30.7 (6.6)
411 (1.4)
<0.001*
Smoking status, n (%)
Current smoker
Never smoked
Ex-smoker
missing
252 (38)
227 (35)
139 (21)
39 (6)
5442 (18)
11798 (40)
10634 (36)
1822 (6)
<0.001**
Age at diabetes diagnosis, 
mean years(SD)
54.3 (14.5) 56.9 (16.9) <0.001*
Years since diabetes 
diagnosis, median (IQR)
1 (1-6) 1(1-5) Z=0.001***
SMI type, n (%)
Schizophrenia
Bipolar disorder
Other psychosis
More than one type
295 (45)
194 (30)
115 (18)
53 (8)
Age at SMI diagnosis, mean 
years( SD)
45.9 (16.6)
years since onset of SMI 
diagnosis, median years (IQR)
10 (2-20)
Diabetes medication, n (%)
None 
Insulin only
Oral medication only
Both
168 (26)
38 (7)
4.03 (61)
48 (7)
9074 (31)
1509 (5)
16983 (57)
2130 (7)
0.001**
Cardiovascular medication, n 
(%)
None 
ACE inhibitors
K blockers
Anticoagulant
Antiplatelet
129 (20)
265 (40)
29 (4)
21 (3)
218 (23)
4348 (15)
15988 (54)
2307 (8)
1424 (5)
11807 (40)
<0.001**
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: blockers
Calcium channel blocker
Thiazide diuretic
Loop diuretics
Other lipid lowering
Statins
96 (15)
116 (18)
69 (11)
80 (12)
38 (6)
399 (61)
6644 (22)
8577 (29)
5765 (19)
4091 (14)
1458 (5)
18131 (61)
Antipsychotic medication, n 
(%)
None
Typical 
Atypical
Depot
Other
276 (42)
107 (16)
254 (39)
42 (7)
19 (3)
28994 (98)
153 (2)
253 (1)
1 (0)
333 (1)
<0.001**
Lithium or other mood 
stabilizer medication, n (%)
170(26) 421 (1) <0.001**
Antidepressant medication, n 
(%)
None
Tricyclic antidepressants
Selective serotonin reuptake 
inhibitors
Other antidepressant
342 (52)
93 (14)
178 (27)
96 (15)
24727 (83)
2420 (8)
2498 (8)
645 (2)
<0.001**
Additional comorbidities 
count, median (IQR)
1 (0-2) 1 (0-2) Z=0.08***
Comorbidities, n (%)
Asthma
Cancer
Coronary heart disease
Chronic kidney disease
Chronic obstructive 
pulmonary disease
Dementia
Depression
Epilepsy
Heart failure
Hypertension
Hypothyroidism 
Osteoarthritis
Osteoporosis
Stroke
81 (12.)
37 (6)
73 (11)
45 (7)
25 (4)
25 (4)
48 (7)
37 (6)
24 (4)
250 (38)
94 (14)
89 (14)
18 (3)
54 (8)
3578 (12)
2255 (8)
5317 (18)
1640 (6)
1252 (4)
374 (1)
820 (3)
404 (1)
1394 (5)
15925 (54)
2190 (7)
5676 (19)
622 (2)
1965 (7)
0.56 ****
0.55 **** 
0.02 ****
0.01 ****
0.67 ****
0.01 ****
0.01 ****
0.01 ****
0.96 ****
<0.001 ****
<0.001 ****
0.02 ****
0.19 ****
<0.001 ****
SMI severe mental illness, BMI body mass index, SD standard deviation, IQR inter quartile range, 
IMD index of multiple deprivation, * t-test, ** 2 test, *** Wilcoxon rank sum test, **** logistic 
regression adjusting for age and gender. Data for medication categories are not mutually exclusive 
as patients could be prescribed more than one. Comparisons of medication between groups were 
made in those with no reported medication compared to those with at least one medication. 
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Table 2 Beta coefficients and odds ratios for patients with SMI compared to controls from univariate and multivariate multilevel mixed effect regression 
models for cardiovascular risk factors
Regression Model Cholesterol HbA1c Systolic Blood 
Pressure
Diastolic blood 
Pressure
Multilevel mixed effect linear regression model, Beta (SE, P)
Model 1
Model 2
Model 3
0.05 (0.05, 0.31)
-0.08 (0.05, 0.13)
-0.07 (0.05, 0.19)
0.04 (0.05, 0.41)
-0.05 (0.05, 0.32)
-0.08 (0.05, 0.09)
-4.32 (0.49, <0.001)
-3.06 (0.46, <0.001)
-2.49 (0.45, <0.001)
0.10 (0.29, 0.74)
-0.51 (0.25, 0.04)
-0.30 (0.25, 0.22)
Multilevel mixed effect binary logistic regression model, OR (95% CI)
Model 1
Model 2
Model 3
1.28 (0.91-1.78)
0.93 (0.67-1.31)
0.94 (0.68-1.33)
1.60 (1.34-1.90)
1.40 (1.18-1.66)
1.38 (1.16-1.64)
2.60 (2.01-3.34)
1.83 (1.45-2.32)
1.76 (1.40-2.21)
0.95 (0.82-1.12)
1.02 (0.88-1.19)
1.02 (0.87-1.18)
Table 3 Percentage of patient-years with high risk levels of outcomes over all patient-years
SMI Controls
Cholesterol, % (95% CI)
Below 2.5mmol/l
Above 6.5mmol/l
0 (0, 1)
4 (3, 5.)
1 (1, 1)
3 (3, 3)
HbA1c, % (95% CI)
Below 6.25% (<45 mmol/mol)
Above 7.75% (61mmol/mol)
27 (25, 28)
32 (30, 34)
19 (19, 20)
31 (30, 31)
Systolic, % (95% CI) 
Below 115mmHg 29 (26, 29) 18 (17, 18)
Diastolic, % (95% CI)
Below 72.5mmHg
Above 92.5mmHg
28 (26, 30)
4 (3, 4)
30 (30, 30)
4 (3, 4)
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Figure 1 Mean levels of outcomes in diabetes patients with comorbid SMI and in non-SMI controls by year of follow-up
(a) Cholesterol
(b) HbA1c
(c) Systolic blood pressure
(d) Diastolic blood pressure
Figure 2 Percentage of diabetes patients with high risk levels of outcomes by year of follow-up 
(a) Cholesterol <2.5mmol/l or >6.5mmol/l
(b) HbA1c <6.25% or >7.75% (<45 or >61mmol/mol)
(c) Systolic blood pressure <115mmHg
(d) Diastolic blood pressure <72.5mmHg or >92.5mmHg
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(a) Cholesterol 
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(b) HbA1c 
244x177mm (72 x 72 DPI) 
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(c) Systolic blood pressure 
244x177mm (72 x 72 DPI) 
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(  iastolic blood pressure 
244x177mm (72 x 72 DPI) 
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(a) Cholesterol <2.5mmol/l or >6.5mmol/l 
244x177mm (72 x 72 DPI) 
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 	 <6.
 or >7.7 (<45 or >61mmol/mol) 
244x177mm (72 x 72 DPI) 
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Table S1. Cohort characteristics across follow-up from baseline year
Follow-up (years) 1 2 3 4 5 6 7 8 9 10 11 12
SMI, n (%) 657 (100) 521 (79.3) 423 (64.4) 328 (49.9) 270 (41.1) 213 (32.4) 175 (26.6) 127 (19.3) 94 (14.3) 67 (10.2) 48 (7.3) 33 (5.0)
Control n (%) 29696 
(100)
25679 
(86.5)
21766 
(73.3)
18473 
(62.2)
15611 
(52.6)
13059 
(44.0)
10893 
(36.7)
8771 
(29.5)
6758 
(22.8)
5287 
(17.8)
3862 
(13.0)
2635 (8.9)
Serum cholesterol 
measurement, n (%)
SMI
Control 
537 (81.7)
23816 
(80.2)
403 (77.4)
20949 
(81.5)
338 (79.9)
18295 
(84.1)
275 (83.8)
15839 
(85.7)
229 (84.8)
13475 
(86.3)
172 (80.8)
11275 
(86.3)
152 (86.9)
9416 
(86.4)
106 (83.5)
7594 
(86.6)
84(89.4)
5838
(86.4)
56(83.4)
4546 
(86.0)
40 (83.3)
3322
(86.0)
24 (72.7)
2234 
(84.8)
HbA1c measurement, n 
(%)
SMI
Control
527 (80.2)
23334 
(78.6)
434 (83.3)
21677 
(84.4)
368 (87.0)
19321 
(88.8)
285 (86.9)
16742 
(90.6)
236 (87.4)
14269 
(91.4)
187 (87.8)
11989 
(91.8)
155 (88.6)
10037 
(92.1)
110 (86.6)
8077 
(92.1)
89 (94.7)
6269 
(92.8)
60 (89.6)
4895 
(92.6)
45(93.8)
3597 
(93.1)
28 (84.9)
2427 
(92.1)
Blood pressure 
measurement, n (%)
SMI
Control
598 (91.0)
27399 
(92.2)
462 (88.9)
23769 
(92.6)
395 (93.4)
20357 
(93.5)
296 (90.2)
17511 
(94.8)
246 (91.1)
14848 
(95.1)
199 (93.4)
12378
(94.8)
164 (93.7)
10342 
(95.0)
119 (93.7)
8327 
(95.0)
89 (94.7)
6423
(95.0)
63 (94.0)
3646
(94.4)
45 (93.8)
3646 
(94.4)
29 (87.8)
2505
(95.0)
Percentages of patients in groups are displayed in relation to follow up year 1. Percentages of vascular risk factor measurements are displayed in relation to 
total number of patients in corresponding year.   
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1 Table S2. Beta coefficients of independent variable and covariates in multilevel mixed effect linear regression model for vascular risk factors
Cholesterol HbAa1c
Model 1 ! (95%CI) Model 2 ! (95%CI) Model 3 ! (95% CI) Model 1 ! (95%CI) Model 2 ! (95%CI) Model 3 ! (95%CI)
Control
SMI
REF
0.05 (-0.05, 0.16)
REF
-0.08 (-0.18, 0.24)
REF
-0.07 (-0.17, 0.03)
REF
0.04 (-0.05, 0.14)
REF
-0.05 (-0.15, 0.05)
REF
-0.08 (-018, 0.01)
Gender
Males
Females
REF
0.39 (0.36, 0.42)
REF
0.38 (0.35, 0.41)
REF
-0.04 (-0.07, -0.02)
REF
-0.02 (-0.04, 0.01)
Age -0.01 (-0.01, -0.01) -0.01 (-0.01, -0.01) -0.01 (-0.01, -0.01) -0.02 (-0.01, -0.02)
BMI -0.01 (-0.01, -0.01) -0.01 (-0.01, -0.01) 0.01 (0.01, 0.01) 0.01 (0.01, 0.01)
Smoking status 
Never
Current
Ex-smoker
REF
0.05 (0.01, 0.09)
-0.02 (-0.01, 0.02)
REF
0.06 (-0.01, 0.10)
-0.01 (-0.04, 0.02)
REF
0.08 (0.05, 0.11)
0.01 (-0.01, 0.03)
REF
0.08 (0.05, 0.11)
0.01 (-0.01, 0.03)
Ethnicity 
White
Mixed
South Asian
Black
Chinese/other
REF
-0.04 (0.02, 0.07)
-0.15 (-0.21, -0.09)
-0.03 (-0.11, 0.57)
-0.09 (-0.21, 0.22)
REF
-0.08 (-0.28, 0.12)
-0.13 (-0.20, -0.07)
-0.04 (-0.12, 0.04)
-0.09 (-0.21, 0.02)
REF
0.08 (-0.11, 0.27)
0.17 (0.12, 0.22)
0.19 (0.11, 0.27)
0.20 (0.10, 0.30)
REF
0.08 (-0.11, 0.26)
0.12 (0.09, 0.18)
0.16 (0.09, 0.24)
0.18 (0.08, 0.27)
IMD quintile
1 (most affluent)
2
3
4
5 (most deprived)
REF
-0.04 (-0.09, 0.01)
-0.02 (-0.07, 0.03)
-0.05 (-0.10, -0.01)
-0.04 (-0.10, 0.01)
REF
-0.04 (-0.08, 0.01)
-0.02 (-0.07, 0.30)
-0.04 (-0.09, 0.01)
-0.03 (-0.09, 0.02)
REF
0.04 (-0.01, 0.09)
0.09 (0.04, 0.14)
0.11 (0.06, 0.17)
0.19 (0.14, 0.25)
REF
0.03 (-0.01, 0.08)
0.07 (0.02, 0.11)
0.09 (0.04, 0.14)
0.17 (0.11, 0.23)
Comorbidities
Asthma
Cancer
CHD
CKD
COPD
Dementia
Depression
Epilepsy
Heart failure
Hypertension
Hypothyroidism 
Osteoarthritis
Osteoporosis
Stroke
0.03 (-0.2, 0.07)
-0.06 (-0.11, -0.01)
-0.19 (-0.23, -0.15)
-0.18 (-0.22, -0.14)
-0.05 (-0.12, 0.24)
-0.03 (-0.17, 0.11)
0.09 (0.01, 0.17)
0.08 (-0.04, 0.20)
-0.09 (-0.15, -0.02)
-0.13 (-0.16, -0.10)
-0.01 (-0.06, -0.04)
-0.04 (-0.07, -0.01)
0.01 (-0.08, 0.09)
-0.02 (-0.08, 0.03)
0.03 (-0.02, 0.07)
-0.06 (-0.11, -0.01)
-0.13 (-0.17, -0.09)
-0.14 (-0.18, -0.09)
-0.05 (-0.11, 0.02)
-0.07 (-0.21, 0.07)
0.09 (0.01, 0.18)
0.10 (-0.02, 0.21)
-0.10 (-0.16, -0.03)
-0.09 (-0.12, -0.06)
-0.01 (-0.05, 0.05)
-0.03 (-0.06, 0.01)
0.01 (-0.08, 0.08)
0.01 (-0.05, 0.06)
-0.01 (-0.04, 0.04)
-0.03 (-0.07, 0.04)
0.06 (0.02, 0.09)
-0.06 (-0.08, -0.03)
0.02 (-0.03, 0.07)
-0.03 (-0.12, 0.06)
0.02 (-0.02, 0.07)
-0.13 (-0.22, -0.02)
0.14 (0.09, 0.19)
-0.13 (-0.15, -0.11)
0.04 (-0.01, 0.08)
-0.08 (-0.10, -0.04)
-0.07 (-0.13, -0.01)
-0.04 (-0.08, 0.01)
-0.01 (-0.04, 0.03)
-0.06 (-0.09, -0.01)
0.03 (-0.01, 0.06)
-0.13 (-0.16, -0.11)
0.03 (-0.02, 0.07)
-0.07 (-0.17, 0.02)
-0.02 (-0.02, 0.06)
-0.16 (-0.26, -0.07)
0.12 (0.07, 0.17)
-0.16 (-0.18, -0.13)
0.02 (-0.02, 0.05)
-0.09 (-0.11, -0.06)
-0.10 (-0.16, -0.04)
-0.07 (-0.11, -0.03)
Years since diabetes diagnosis -0.01 (-0.01, -0.01) 0.04 (0.04, 0.05)
Cardiovascular medication
Statin
Other lipid lowering
-0.43 (-0.46, -0.40)
0.29 (0.24, 0.34)
2
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3 Table S2 continue
Systolic blood pressure Diastolic blood pressure
Model 1 ! (95%CI) Model 2 ! (95%CI) Model 3 ! (95%CI) Model 1 ! (95%CI) Model 2 ! (95%CI) Model 3 ! (95%CI)
Control
SMI
REF
-4.32 (-5.30, 3.36)
REF
-3.06 (-3.96, -2.16)
REF
-2.50 (-3.37, -1.62)
REF
0.09 (-0.46, 0.66)
REF
-0.51 (-1.02, -0.02)
REF
-0.30 (-0.80, 0.18)
Gender
Males
Females
REF
0.59 (0.32, 0.86)
REF
0.72 (0.46, 0.98)
REF
-0.37 (-0.53, -0.22)
REF
-0.44 (-0.59, -0.29)
Age 0.18 (0.17, 0.19) 0.18 (0.17, 0.19) -0.17 (-0.18, -0.16) -0.14 (-0.15, -0.13)
BMI 0.13 (0.11, 0.15) 0.12 (0.10, 0.13) 0.14 (0.14, 0.15) 0.15 (0.14, 0.16)
Smoking status 
Never
Current
Ex-smoker
REF
-0.25 (-0.57, 0.75)
-0.20 (-0.45, 0.04)
REF
-0.14 (-0.45, 0.18)
-0.19 (-0.43, 0.05)
REF
-0.33 (-0.53, -0.14)
-0.36 (-0.50, -0.21)
REF
-0.30 (-0.49, -0.11)
-0.36 (-0.50, -0.22)
Ethnicity 
White
Mixed
South Asian
Black
Chinese/other
REF
-1.53 (-3.55, 0.50)
-1.45 (-1.94, -0.96)
0.89 (0.18, 1.60)
-1.73 (-2.73, -0.74)
REF
-1.60 (-3.54, 0.34)
-1.33 (-1.81, -0.84)
0.54 (-0.15, 1.22)
-1.68 (-2.65, -0.70)
REF
0.51 (-0.53, 1.54)
0.08 (-0.23, 0.38)
1.28 (0.93, 1.64)
0.35 (-0.25, 0.94)
REF
0.48 (-0.55, 1.51)
0.25 (-0.06, 0.55)
1.36 (1.01, 1.72)
0.43 (-0.15, 1.02)
IMD quintile
1 (most affluent)
2
3
4
5 (most deprived)
REF
0.09 (-0.35, 0.53)
0.64 (-0.41, 0.54)
0.07 (-0.41, 0.56)
0.09 (-0.45, 0.63)
REF
0.15 (-0.28, 0.57)
0.01 (-0.36, 0.56)
0.16 (-0.31, 0.63)
0.16 (-0.37, 0.69)
REF
0.08 (-0.16, 0.32)
-0.12 (-0.38, 0.13)
-0.40 (-0.67, -0.13)
-0.39 (-0.69, -0.09)
REF
0.14 (-0.09, 0.37)
-0.03 (-0.28, 0.22)
-0.23 (-0.49, 0.03)
-0.26 (-0.55, 0.04)
Comorbidities
Asthma
Cancer
CHD
CKD
COPD
Dementia
Depression
Epilepsy
Heart failure
Hypertension
Hypothyroidism 
Osteoarthritis
Osteoporosis
-0.45 (-0.82, -0.08)
-1.20 (-1.58, -0.83)
-2.07 (-2.38, -1.76)
-3.94 (-4.21, -3.67)
-2.47 (-2.97, -1.97)
-6.02 (-6.86, -5.18)
-0.39 (-0.83, 0.04)
-0.23 (-1.19, 0.73)
-3.57 (-4.24, -3.10)
4.12 (3.88, 4.36)
-1.53 (-1.94, -1.12)
-0.85 (-1.13, -0.56)
-1.20 (-2.11, -1.27)
-0.43 (-0.79, -0.07)
-1.02 (-1.39, -0.66)
-1.78 (-2.09, -1.46)
-3.53 (-3.80, -3.27)
-2.19 (-2.68, -1.71)
-5.20 (-6.03, -4.38)
-0.34 (-0.91, 0.09)
0.03 (-0.90, 0.96)
-2.67 (-3.14, -2.19)
2.14 (1.88, 2.40)
-1.16 (-1.56, -0.77)
-0.72 (-0.99, -0.45)
-0.85 (-1.46, -0.22)
-0.22 (-0.42, -0.02)
-0.68 (-0.88, -0.47)
-1.94 (-2.11, -1.77)
-2.00 (-2.15, -1.85)
-1.22 (-1.50, -0.95)
-0.88 (-1.36, -0.40)
0.17 (-0.05, 0.40)
-0.21 (-0.75, 0.33)
-1.45 (-1.72, -1.19)
1.18 (1.05, 1.31)
-0.65 (-0.88, -0.42)
-0.47 (-0.62, -0.32)
-0.33 (-0.67, 0.02)
-0.21 (-0.41, -0.01)
-0.55 (-0.75, -0.35)
-1.45 (-1.63, -1.28)
-1.52 (-1.67, -1.38)
-1.18 (-1.45, -0.91)
-0.61 (-1.08, -0.14)
0.20 (-0.02, 0.43)
-0.05 (-0.48, 0.58)
-1.06 (-1.32, -0.80)
1.04 (0.90, 1.18)
-0.46 (-0.68, -0.23)
-0.37 (-0.52, -0.22)
-0.10 (-0.45, 0.24)
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Stroke -1.69 (0.22, <0.01) -1.49 (1.90, -1.08) -0.70 (-0.94, -0.47) -0.39 (-0.62, -0.17) 
Years since diabetes diagnosis -0.14 (-0.16, -0.12) -0.22 (-0.23, -0.21)
Cardiovascular medication
ACE inhibitors
: blockers
; blockers
Calcium channel blocker
Thiazide diuretic
Loop diuretics
Other lipid lowering
Statins
2.64 (2.42, 2.84)
3.60 (3.28, 3.92)
0.26 (0.01, 0.50)
2.63 (2.41, 2.84)
1.59 (1.36-1.83)
-1.90 (-2.17, -1.63)
-1.21 (-1.58, -0.87)
-2.29 (-2.49, -2.08)
0.90 (0.79, 1.02)
-0.08 (-0.22, 0.09)
-0.30 (-0.43, -0.16)
-0.08 (-0.19, 0.03)
0.39 (0.26, 0.52)
-0.87 (-1.02, -0.73)
-0.74 (-0.94, -0.54)
-1.01 (-1.12, -0.90)
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Table S3.  Odds ratios of at high risk levels and covariates in multilevel mixed effect binary regression model for vascular risk factors
Cholesterol HbAa1c
Model 1 OR (95% CI) Model 2 OR (95% CI) Model 3 OR (95% CI) Model 1 OR (95% CI) Model 2 OR (95% CI) Model 3 OR (95% CI)
Control
SMI
REF
1.28 (0.91, 1.78)
REF
0.93 (0.67, 1.31)
REF
0.95 (0.68, 1.32)
REF
1.60 (1.34, 1.90)
REF
1.40 (1.18, 1.67)
REF
1.38 (1.16, 1.64)
Gender
Males
Females
REF
1.99 (1.79, 2.21)
REF
1.95 (1.76, 2.16)
REF
1.01 (0.96, 1.07)
REF
1.02 (0.97, 1.06)
Age 0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 0.97 (0.96, 0.98)
BMI 0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 0.98 (0.97, 0.99)
Smoking status 
Never
Current
Ex-smoker
REF
1.49 (1.32, 1.67)
1.01 (0.92, 1.10)
REF
1.50 (1.33, 1.69)
1.01 (0.91, 1.11)
REF
1.11 (1.05, 1.17)
1.06 (1.01, 1.10)
REF
1.11 (1.05, 1.18)
1.06 (1.01, 1.11)
Ethnicity 
White
Mixed
South Asian
Black
Chinese/other
REF
1.00 (0.57, 1.75)
0.72 (0.57, 0.92)
0.73 (0.56, 0.94)
0.83 (0.56, 1.22)
REF
0.98 (0.56, 1.70)
0.74 (0.58, 0.95)
0.72 (0.56, 0.94)
0.84 (0.57, 1.23)
REF
0.98 (0.72, 1.32)
0.97 (0.89, 1.06)
1.07 (0.96, 1.20)
0.99 (0.83, 1.21)
REF
0.98 (0.73, 1.32)
0.94 (0.86, 1.03)
1.05 (0.94, 1.17)
0.98 (0.81, 1.19)
IMD quintile
1 (most affluent)
2
3
4
5 (most deprived)
REF
1.00 (0.86, 1.16)
1.07 (0.91, 1.25)
1.08 (0.91, 1.27)
1.06 (0.89, 1.26)
REF
1.01 (0.87, 1.17)
1.08 (0.82, 1.30)
1.11 (0.93, 1.30)
1.09 (0.92, 1.29)
REF
1.02 (0.95, 1.09)
1.13 (1.04, 1.23)
1.09 (1.01, 1.19)
1.16 (1.06, 1.27)
REF
1.01 (0.94, 1.08)
1.11 (1.03, 1.21)
1.07 (1.00, 1.16)
1.14 (1.05, 1.25)
Comorbidities
Asthma
Cancer
CHD
CKD
COPD
Dementia
Depression
Epilepsy
Heart failure
Hypertension
Hypothyroidism 
0.90 (0.79, 1.04)
1.11 (0.94, 1.32)
0.90 (0.79, 1.02)
0.77 (0.68, 0.87)
1.06 (0.86, 1.30)
1.33 (0.92, 1.92)
1.19 (0.98, 1.43)
1.04 (0.73, 1.48)
1.42 (1.18, 1.71)
0.75 (0.68, 0.82)
1.21 (1.03, 1.42)
0.90 (0.79, 1.03)
1.09 (0.93, 1.30)
0.95 (0.84, 1.08)
0.79 (0.69, 0.89)
1.04 (0.85, 1.28)
1.30 (0.90, 1.88)
1.19 (1.00, 1.43)
1.07 (0.76, 1.54)
1.42 (1.19, 1.72)
0.79 (0.72, 0.86)
1.23 (1.05, 1.44)
0.95 (0.88, 1.01)
0.93 (0.87, 0.99)
0.98 (0.94, 1.04)
1.02 (0.97, 1.08)
1.00 (0.92, 1.10)
1.64 (1.40, 1.94)
1.07 (0.98, 1.18)
1.04 (0.88, 1.24)
1.17 (1.01, 1.28)
0.93 (0.89, 0.97)
1.09 (1.01, 1.18)
0.95 (0.89, 1.01)
0.92 (0.86, 0.99)
0.96 (0.91, 1.02)
0.97 (0.92, 1.03)
1.01 (0.93, 1.11)
1.59 (1.34, 1.87)
1.07 (0.98, 1.17)
1.02 (0.86, 1.21)
1.15 (1.06, 1.26)
0.92 (0.88, 0.96)
1.08 (0.99, 1.16)
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Osteoarthritis
Osteoporosis
Stroke
0.95 (0.85, 1.06)
1.26 (0.97, 1.64)
1.05 (0.88, 1.25)
0.95 (0.85, 1.06)
1.26 (0.97, 1.63)
1.10 (0.93, 1.32)
0.95 (0.90, 1.00)
1.16 (1.03, 1.31)
1.13 (1.04, 1.22)
0.95 (0.90, 0.99)
1.13 (1.00, 1.28)
1.10 (1.01, 1.19)
Years since diabetes diagnosis 0.97 (0.96, 0.98) 1.03 (1.02, 1.04)
Cardiovascular medication
Statin
Other lipid lowering
0.62 (0.57, 0.67)
1.78 (1.56, 2.01)
Table S3 continued
Systolic blood pressure Diastolic blood pressure
Model 1 OR (95% CI) Model 2 OR (95% CI) Model 3 OR (95% CI) Model 1 OR (95% CI) Model 2 OR (95% CI) Model 3 OR (95% CI)
Control
SMI
REF
2.60 (2.01, 3.34)
REF
1.83 (1.45, 2.31)
REF
1.76 (1.40, 2.21)
REF
0.95 (0.82, 1.12)
REF
1.02 (0.88, 1.19)
REF
1.02 (0.84, 1.18)
Gender
Males
Females
REF
1.16 (1.06, 1.25)
REF
1.06 (0.96, 1.16)
REF
1.02 (0.98, 1.07)
REF
1.04 (0.99, 1.08)
Age 0.97 (0.96, 0.98) 0.97 (0.96, 0.98) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03)
BMI 0.95 (0.94, 0.96) 0.95 (0.94, 0.96) 0.97 (0.96, 0.98) 0.97 (0.96, 0.98)
Smoking status 
Never
Current
Ex-smoker
REF
1.25 (1.14, 1.39)
1.08 (0.99, 1.18)
REF
1.26 (1.15, 1.39)
1.08 (0.95, 1.17)
REF
1.14 (1.07, 1.20)
1.04 (1.01, 1.10)
REF
1.14 (1.08, 1.21)
1.05 (1.01, 1.09)
Ethnicity 
White
Mixed
South Asian
Black
Chinese/other
REF
1.08 (0.62, 1.88)
1.26 (1.06, 1.51)
0.82 (0.64, 1.05)
1.27 (0.92, 1.76)
REF
1.08 (0.62, 1.87)
1.27 (1.06, 1.51)
0.88 (0.70, 1.12)
1.31 (0.95, 1.80)
REF
0.79 (0.57, 1.10)
0.98 (0.88, 1.08)
0.89 (0.78, 1.06)
0.80 (0.68, 0.97)
REF
0.80 (0.58, 1.11)
0.94 (0.86, 1.05)
0.85 (0.75, 0.96)
0.80 (0.67, 0.95)
IMD quintile
1 (most affluent)
2
3
4
5 (most deprived)
REF
1.06 (0.94, 1.21)
1.05 (0.91, 1.20)
1.11 (0.97, 1.29)
1.21 (1.03, 1.41)
REF
1.05 (0.93, 1.19)
1.03 (0.90, 1.18)
1.10 (0.96, 1.27)
1.20 (1.03, 1.39)
REF
0.96 (0.90, 1.03)
1.04 (0.97, 1.12)
1.12 (1.04, 1.21)
1.14 (1.05, 1.24)
REF
0.95 (0.89, 1.02)
1.02 (0.95, 1.10)
1.08 (1.01, 1.18)
1.12 (1.02, 1.21)
Comorbidities
Asthma 0.93 (0.83, 1.04) 0.96 (0.86, 1.08) 1.01 (0.95, 1.07) 1.01 (0.95, 1.07)
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43
44
45
46
For Peer Review
Cancer
CHD
CKD
COPD
Dementia
Depression
Epilepsy
Heart failure
Hypertension
Hypothyroidism 
Osteoarthritis
Osteoporosis
Stroke
1.11 (0.98, 1.25)
1.76 (1.61, 1.93)
1.46 (1.31, 1.61)
1.43 (1.23, 1.67)
4.16 (3.29, 5.25)
1.18 (1.01, 1.37)
1.08 (0.81, 1.46)
2.90 (2.54, 3.31)
0.30 (0.28, 0.33)
1.19 (1.05, 1.35)
1.08 (0.99, 1.20)
1.18 (0.96, 1.45)
1.50(1.31, 1.70)
1.08 (0.96, 1.23)
1.58 (1.43, 1.75)
1.41 (1.28, 1.56)
1.37 (1.17, 1.60)
3.93 (3.11, 4.94)
1.16 (1.00, 1.35)
1.05 (0.79, 1.41)
2.02 (1.76, 2.32)
0.39 (0.36, 0.42)
1.15 (1.01, 1.30)
1.07 (0.98, 1.17)
1.14 (0.94, 1.40)
1.49 (1.31, 1.70)
1.10 (1.04, 1.18)
1.50 (1.43, 1.57)
1.65 (1.57, 1.73)
1.27 (1.17, 1.38)
1.39 (1.19, 1.61)
1.02 (0.94, 1.12)
0.98 (0.83, 1.15)
1.60 (1.47, 1.72)
0.77 (0.73, 0.80)
1.12 (1.05, 1.21)
1.06 (1.01, 1.11)
1.07 (0.96, 1.18)
1.16 (1.08, 1.25)
1.09 (1.02, 1.16)
1.34 (1.28, 1.41)
1.52 (1.44, 1.60)
1.27 (1.17, 1.39)
1.39 (1.20, 1.62)
1.01 (0.92, 1.10)
0.94 (0.81, 1.10)
1.41 (1.30, 1.52)
0.68 (0.65, 0.71)
1.11 (1.04, 1.19)
1.06 (1.01, 1.10)
1.04 (0.93, 1.16)
1.01 (1.02, 1.18)
Years since diabetes diagnosis 1.00 (0.99, 1.01) 1.03 (1.02, 1.04)
Cardiovascular medication
ACE inhibitors
: blockers
; blockers
Calcium channel blocker
Thiazide diuretic
Loop diuretics
Other lipid lowering
Statins
0.85 (0.79, 0.92)
0.67 (0.58, 0.77)
1.29 (1.18, 1.40)
0.57 (0.52, 0.62)
0.85 (0.77, 0.94)
1.91 (1.74, 2.10)
0.98 (0.86, 1.11)
0.98 (0.91, 1.06)
1.06 (1.02, 1.10)
1.22 (1.15, 1.29)
1.10 (1.05, 1.15)
1.16 (1.12, 1.21)
0.96 (0.92, 0.99)
1.28 (1.22, 1.35)
1.02 (0.95, 1.08)
1.03 (0.98, 1.06)
Liu, N. H., Daumit, G. L., Dua, T., et al. (2017). Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities 
for clinical practice, policy and research agendas. World Psychiatry, 16, 30-40.
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